Clinical trial Recruiting at 3 sites Observational Ages 21 to 80

AI platform for CT coronary angiography applications

Official title: AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry (APOLLO)

Run by National Heart Centre Singapore · NCT05509010 · Data updated 2026-11-12

This study is testing a new AI platform that helps doctors quickly and accurately analyze heart scans for patients with coronary artery disease to improve their treatment and care.

Quick facts

Study typeObservational
Ages21 Years to 80 Years
SexAll
Enrollment8000 (estimated)
SponsorNational Heart Centre Singapore
Academic / other
Drugs / interventionsradiation
Locations3 sites (Singapore and 2 other locations)
StatusRecruiting
StartedOctober 1, 2021
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedAugust 19, 2022
Trial IDNCT05509010 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals aged 21 and older who are clinically indicated for evaluation by CT coronary angiography.

Probably not a fit

Patients with known complex congenital heart disease or those requiring immediate invasive angiography for reasons other than CAD may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop an AI-driven national platform for CT coronary angiography that automates the processes of anonymization, reporting, Agatston scoring, and plaque quantification in patients with coronary artery disease (CAD). By leveraging artificial intelligence, the platform seeks to enhance diagnostic accuracy and efficiency, reducing the time required for report generation and minimizing inter-observer variability. The initiative addresses the growing prevalence of CAD and aims to improve clinical management and prognosis through better prediction of pharmacotherapy responses.

Why it matters

Potential benefit: If successful, this platform could significantly streamline the diagnostic process for CAD, leading to improved patient outcomes and more effective treatment strategies.

How similar studies have gone: Other studies have shown success with AI applications in medical imaging, indicating a promising potential for this approach in improving CAD diagnostics.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥21 years old
2. Signed informed consent
3. Clinically indicated for evaluation by CTCA

Exclusion Criteria:

1. Individuals unable to provide informed consent
2. Known complex congenital heart disease
3. Planned invasive angiography for reasons other than CAD
4. Non-cardiac illness with life expectancy \< 2 years
5. Pregnancy
6. Concomitant participation in another clinical trial in which subject is subject to investigational drug or device
7. Cardiac event and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) and/or valvular repair/replacement prior to CTCA
8. Glomerular Filtration Rate ≤ 30mL/min
9. Known allergy to iodinated contrast agent
10. Contraindications to beta blockers or nitroglycerin or adenosine

Where it's running

  • National Heart Centre Singapore
    Singapore, Singapore
    Recruiting
  • National University Hospital
    Singapore, Singapore
    Recruiting
  • Tan Tock Seng Hospital
    Singapore, Singapore
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.